Table 4.
Concordance between Drug Dosing Recommendations using Measured Glomerular Filtration Rate (top) and the Cockcroft-Gault Equation (bottom) Versus Estimated Kidney Function for specific drug examples
| Drug (Dosing levels) | CKD-EPI | MDRD Study | Cockcroft-Gault |
|---|---|---|---|
|
|
|||
| Concordant (%) Kappa (95% CI) |
Concordant (%) Kappa (95% CI) |
Concordant (%) Kappa (95% CI) |
|
| Comparison with Measured Glomerular Filtration Rate | |||
|
| |||
| Tenofovir (5); Emtricitabine (4) | 95 0.60 (0.36, 0.84) |
93 0.52 (0.28, 0.75) |
93 0.49 (0.23, 0.75) |
| Tenofovir/ emtricitabine (3) | 95 0.60 (0.36, 0.84) |
93 0.52 (0.28, 0.75) |
93 0.49 (0.23, 0.75) |
| Tenofovir/ emtricitabine/ efavirenz; Abacavir/ lamivudine (2) |
95 0.53 (0.29, 0.77) |
93 0.46 (0.23, 0.70) |
93 0.41 (0.16, 0.65) |
|
| |||
| Comparison with the Cockcroft-Gault Equation | |||
|
| |||
| Tenofovir (5); Emtricitabine (4)a | 96 0.75 (0.57, 0.93) |
94 0.66 (0.47, 0.85) |
- |
| Tenofovir/ emtricitabine (3)a | 96 0.75 (0.57, 0.93) |
94 0.66 (0.47, 0.85) |
- |
| Tenofovir/ emtricitabine/ efavirenz; Abacavir/ lamivudine (2) |
96 0.71 (0.52, 0.90) |
95 0.64 (0.44, 0.84) |
- |
Abbreviations: mGFR, measured GFR; CKD-EPI, Chronic Kidney Disease Epidemiology collaboration; MDRD Study, Modification of Diet in Renal Disease Study
Tenofovir (Viread®), tenofovir/ emtricitabine (Truvada®), tenofovir/ emtricitabine/ efavirenz (Atripla™), abacavir/ lamivudine (Epzicom™)
p<0.05 for difference in concordance rates among kidney function estimates
Dosing recommendations from Panel on Antiretroviral Guidelines for Adults and Adolescents.
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.
Department of Health and Human Services. October 14, 2011; 1-166 [3].